Related Experiment Videos
Low-dose aspirin in pregnancy.
B M Sibai1, R Mirro, C M Chesney
1Department of Obstetrics and Gynecology, University of Tennessee, Memphis.
Obstetrics and Gynecology
|October 1, 1989
Summary
Low-dose aspirin significantly reduced maternal thromboxane production but did not affect neonatal levels or circulation. Higher aspirin doses (60-80mg) were more effective in inhibiting maternal platelet thromboxane B2 production.
Area of Science:
- Obstetrics and Gynecology
- Pharmacology
- Neonatal Medicine
Background:
- Low-dose aspirin is used in pregnancy to manage certain conditions.
- The effects of varying aspirin doses on maternal and neonatal prostaglandin and thromboxane levels require further clarification.
Purpose of the Study:
- To evaluate the impact of low-dose aspirin (20, 60, 80 mg/day) on maternal and neonatal 6-keto-prostaglandin F1 alpha and thromboxane B2 levels.
- To assess aspirin's effects on maternal platelet aggregation and neonatal transitional circulation.
Main Methods:
- Prospective randomized study involving 40 pregnant women near term.
- Maternal and neonatal plasma levels of 6-keto-PGF1 alpha and thromboxane B2 were measured.
- Maternal platelet aggregation and thromboxane production were assessed in response to adenosine diphosphate and collagen.
Main Results:
- Maternal serum 6-keto-PGF1 alpha levels were unaffected by aspirin doses.
- Maternal thromboxane B2 production was significantly decreased by 60 and 80 mg aspirin doses.
- Neonatal 6-keto-PGF1 alpha and thromboxane B2 levels, and platelet aggregation, were not affected by any aspirin doses.
Conclusions:
- Low-dose aspirin effectively reduces maternal thromboxane production in a dose-dependent manner.
- Neonatal hemostasis and circulation appear unaffected by maternal low-dose aspirin therapy.
- Higher doses of aspirin (60-80 mg) show greater inhibition of maternal thromboxane production.